Boehringer Mannheim (Germany) announces hepatitis G test:
This article was originally published in Clinica
Boehringer Mannheim (Germany) has developed a nucleic acid-based test for the recently sequenced hepatitis G virus. Prof Georg Hess told Clinica that the assay uses 30 rounds of PCR to amplify the virus and a two-probe, streptavidin system to detect it calorimetrically on the company's ES 300 immunoanalyser. The test can detect 1,000 genome equivalents/ml. Approximately 1-2% of the population carries hepatitis G, which is transfusion transmissible. The genetic sequence of the virus was published in the January 26th issue of Science.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.